Johnson & Johnson reports positive results for Talvey in combination with Darzalex Faspro, pomalidomide and Tecvayli in the ...
On Friday, Johnson & Johnson (NYSE:JNJ) released updated results from the investigational Phase 1b RedirecTT-1 study ...
10h
Data from the Phase 3 AURIGA study show Darzalex Faspro plus lenalidomide maintenance therapy following autologous stem cell transplant (ASCT) significantly increases MRD-negative conversion rates at ...
An oral session Friday at the International Myeloma Society 21st Annual Meeting & Exposition offered updates for the TRIMM-2 ...
The trial is seen as a complement to the MAIA trial, which had shown a significant overall survival benefit with daratumumab ...
Approval based on positive results from the IMROZ phase 3 study demonstrating Sarclisa in combination with bortezomib, lenalidomide, and dexamethasone (VRd) significantly improved progression-free ...
A new drug combination, talquetamab and teclistamab, shows promising results in treating patients with heavily pretreated ...
US FDA approves anti-CD38 therapy, Sarclisa in combo with standard-of-care treatment for adult patients with NDMM who are not eligible for transplant: Paris Tuesday, September 24, ...
After a long road that included a three-month delay as the agency pushed for additional data, the US FDA has approved Sanofi ...
The FDA approved Sanofi's Sarclisa (isatuximab) in combination with VRd as a first-line treatment for newly diagnosed ...
The FDA has approved Sarclisa (isatuximab) as a first-line therapy for blood cancer multiple myeloma as a combination regimen ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback